Background Locoregional therapy (LRT) in de novo metastatic disease is controversial with
inconsistent results from randomized control trials (RCTs). Methods RCTs comparing LRT …

Improvements in systemic therapies have changed the face of de novo metastatic breast
cancer (dnMBC), with a 5-year survival rate exceeding 25%. Increasing evidence suggests …

Simple Summary Approximately 8% of breast cancers are diagnosed with synchronous
distant metastasis at initial diagnosis, a situation known as de novo metastatic disease …

Introduction Improvement in overall survival (OS) by locoregional treatment (LRT) of the
primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial …

A number of studies have recently demonstrated a survival benefit in stage IV breast cancer
patients following surgical resection of the primary tumor. Here, we investigate the …

Background The role of locoregional treatment in women with metastatic breast cancer at
first presentation is unclear. Preclinical evidence suggests that such treatment might help the …

Metastatic breast cancer (MBC) at presentation (Stage IV) is a devastating diagnosis with a
poor prognosis and a 5-year overall survival rate not exceeding 20%. The treatment is …

Patients presenting with de novo stage IV metastatic breast cancer have a complex disease
which is normally treated with palliative intent and systemic therapy. However, there is …

Background Until 2001, the paradigm guiding the management of women with de novo
metastatic breast cancer (dnMBC) stipulated that primary-site locoregional therapy (PSLT) …

Background The impact of locoregional treatment (LRT) on overall survival (OS) in de novo
metastatic breast cancer (dnMBC) is still under debate, with very few data available …